Bauke Schievink1, Dick de Zeeuw1, Hans-Henrik Parving2,3, Peter Rossing4, Hiddo Jan Lambers Heerspink1. 1. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 2. Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen. 3. Department of Medical Endocrinology, Rigshospitalet, HEALTH, Aarhus University, Aarhus, Denmark. 4. Steno Diabetes Center, Gentofte, NNF Center for Basic Metabolic Research University of Copenhagen, Copenhagen, HEALTH, Aarhus University, Aarhus.
Abstract
AIMS: Angiotensin receptor blockers (ARBs) are renoprotective and targeted to blood pressure. However, ARBs have multiple other (off-target) effects which may affect renal outcome. It is unknown whether on-target and off-target effects are congruent within individuals. If not, this variation in short term effects may have important implications for the prediction of individual long term renal outcomes. Our aim was to assess intra-individual variability in multiple parameters in response to ARBs in type 2 diabetes. METHODS: Changes in systolic blood pressure (SBP), albuminuria, potassium, haemoglobin, cholesterol and uric acid after 6 months of losartan treatment were assessed in the RENAAL database. Improvement in predictive performance of renal outcomes (ESRD or doubling serum creatinine) for each individual using ARB-induced changes in all risk markers was assessed by the relative integrative discrimination index (RIDI). RESULTS: SBP response showed high variability (mean -5.7 mmHg, 5(th) to 95(th) percentile -36.5 to +24.0 mmHg) between individuals. Changes in off-target parameters also showed high variability between individuals. No congruency was observed between responses to losartan in multiple parameters within individuals. Using individual responses in all risk markers significantly improved renal risk prediction (RIDI 30.4%, P < 0.01) compared with using only SBP changes. Results were successfully replicated in two independent trials with irbesartan, IDNT and IRMA-2. CONCLUSIONS: In this post hoc analysis we showed that ARBs have multiple off-target effects which vary between and within individuals. Combining all ARB-induced responses beyond SBP provides a more accurate prediction of who will benefit from ARB therapy. Prospective trials are required to validate these findings.
RCT Entities:
AIMS: Angiotensin receptor blockers (ARBs) are renoprotective and targeted to blood pressure. However, ARBs have multiple other (off-target) effects which may affect renal outcome. It is unknown whether on-target and off-target effects are congruent within individuals. If not, this variation in short term effects may have important implications for the prediction of individual long term renal outcomes. Our aim was to assess intra-individual variability in multiple parameters in response to ARBs in type 2 diabetes. METHODS: Changes in systolic blood pressure (SBP), albuminuria, potassium, haemoglobin, cholesterol and uric acid after 6 months of losartan treatment were assessed in the RENAAL database. Improvement in predictive performance of renal outcomes (ESRD or doubling serum creatinine) for each individual using ARB-induced changes in all risk markers was assessed by the relative integrative discrimination index (RIDI). RESULTS: SBP response showed high variability (mean -5.7 mmHg, 5(th) to 95(th) percentile -36.5 to +24.0 mmHg) between individuals. Changes in off-target parameters also showed high variability between individuals. No congruency was observed between responses to losartan in multiple parameters within individuals. Using individual responses in all risk markers significantly improved renal risk prediction (RIDI 30.4%, P < 0.01) compared with using only SBP changes. Results were successfully replicated in two independent trials with irbesartan, IDNT and IRMA-2. CONCLUSIONS: In this post hoc analysis we showed that ARBs have multiple off-target effects which vary between and within individuals. Combining all ARB-induced responses beyond SBP provides a more accurate prediction of who will benefit from ARB therapy. Prospective trials are required to validate these findings.
Authors: Frank A Holtkamp; Dick de Zeeuw; Pieter A de Graeff; Gozewijn D Laverman; Tom Berl; Giuseppe Remuzzi; David Packham; Julia B Lewis; Hans-Henrik Parving; Hiddo J Lambers Heerspink Journal: Eur Heart J Date: 2011-03-18 Impact factor: 29.983
Authors: Norman K Hollenberg; Hans-Henrik Parving; Giancarlo Viberti; Giuseppe Remuzzi; Susan Ritter; Steven Zelenkofske; Albert Kandra; William L Daley; Ricardo Rocha Journal: J Hypertens Date: 2007-09 Impact factor: 4.844
Authors: Janice A Kolberg; Torben Jørgensen; Robert W Gerwien; Sarah Hamren; Michael P McKenna; Edward Moler; Michael W Rowe; Mickey S Urdea; Xiaomei M Xu; Torben Hansen; Oluf Pedersen; Knut Borch-Johnsen Journal: Diabetes Care Date: 2009-07 Impact factor: 19.112
Authors: Y Miao; D Dobre; H J Lambers Heerspink; B M Brenner; M E Cooper; H-H Parving; S Shahinfar; D Grobbee; D de Zeeuw Journal: Diabetologia Date: 2010-09-30 Impact factor: 10.122
Authors: William F Keane; Barry M Brenner; Dick de Zeeuw; Jean-Pierre Grunfeld; Janet McGill; William E Mitch; Artur B Ribeiro; Shahnaz Shahinfar; Roger L Simpson; Steven M Snapinn; Robert Toto Journal: Kidney Int Date: 2003-04 Impact factor: 10.612
Authors: Sergei I Petrykiv; Dick de Zeeuw; Frederik Persson; Peter Rossing; Ron T Gansevoort; Gozewijn D Laverman; Hiddo J L Heerspink Journal: Br J Clin Pharmacol Date: 2017-02-01 Impact factor: 4.335
Authors: Sergei Petrykiv; C David Sjöström; Peter J Greasley; John Xu; Frederik Persson; Hiddo J L Heerspink Journal: Clin J Am Soc Nephrol Date: 2017-03-16 Impact factor: 8.237
Authors: Bauke Schievink; Dick de Zeeuw; Paul A Smink; Dennis Andress; John J Brennan; Blai Coll; Ricardo Correa-Rotter; Fan Fan Hou; Donald Kohan; Dalane W Kitzman; Hirofumi Makino; Hans-Henrik Parving; Vlado Perkovic; Giuseppe Remuzzi; Sheldon Tobe; Robert Toto; Jarno Hoekman; Hiddo J Lambers Heerspink Journal: Eur J Prev Cardiol Date: 2015-07-30 Impact factor: 7.804
Authors: Sophie M van den Belt; Hiddo J L Heerspink; Valentina Gracchi; Dick de Zeeuw; Elke Wühl; Franz Schaefer Journal: J Am Soc Nephrol Date: 2018-06-21 Impact factor: 10.121
Authors: Sergei I Petrykiv; Gozewijn Dirk Laverman; Frederik Persson; Liffert Vogt; Peter Rossing; Martin H de Borst; Ronald T Gansevoort; Dick de Zeeuw; Hiddo J L Heerspink Journal: Clin J Am Soc Nephrol Date: 2017-10-11 Impact factor: 8.237